Summary Report of Consolidated Financial Results
For the Three Months Period ended June 30, 2013
August 12, 2013stCompany name: NIPRO CORPORATION
TSE/OSE-1 section
Code No.8086
URL: http://www.nipro.co.jp/
Representative: Yoshihiko Sano, President and Representative Director
Contact person: Akihiko Yamabe, Director and General Manager of Accounting Division
TEL: (06)6372-2331
Filling date of quarterly reporting: August 14, 2012
Payment date of cash dividends: Supplemental material on quarterly reporting: No
Presentation on quarterly results: No(Note: Amounts are truncated to one million yen)
1. Consolidated Results for the Three Months ended June 30, 2013 (From April 1, 2013 to June 30, 2013)(1) Consolidated Results of Operations(Note: % of change from the same period a year ago)
Net Sales
Operating Income
Ordinary Income
Net Income
Millions of yen% Millions of yen% Millions of yen% Millions of yen%
3 months ended June 30, 2013
70,09319.8
2,534(27.0)
4,322
39.7
2,441
68.9
3 months ended June 30, 2012
58,532
19.1
3,473
0.4
3,092
21.8
1,445 393.9
Note: Comprehensive income

3 months ended June 30, 2013: 24,354 million yen (-%)

3 months ended June 30, 2013
3 months ended June 30, 2012

Earnings per share
Yen
14.31
8.48

(2) Consolidated Financial Position
Total Assets
Millions of yen
3 months ended June 30, 2013
599,115
Year ended March 31, 2013
579,302
Note: Equity

2.

3 months ended June 30, 2012: (2,781) million yen (-%Diluted Earnings per share
Yen
12.92
7.65

Net Assets
Millions of yen
150,289
128,763

3 months ended June 30, 2013: 141,067 million yen

Equity Ratio
%
23.5
20.7

Year ended March 31, 2013: 119,973 million yen

Dividends

Year ended March 31, 2013
Year ending March 31, 2014
Year ending March 31, 2014
(Forecast)First-quarter
Yen-

Annual Dividends per Year
Year-end Dividends
Second-quarter
Third-quarter
Yen
Yen
Yen
12.00
15.50
11.00

-

14.50

Annual Dividends

Yen
27.50
25.50

Note: Revisions to the forecast of cash dividends in the current quarter: No
3. Forecast of Consolidated Financial Results for the Year ending March 31, 2014 (From April 1, 2013 to March 31, 2014)(Note: The % displays in the line of six months ending Sept. 30, 2013 show increase/decrease ratio against the six months
ended Sept. 30, 2012. The % displays in the line of year ending March 31, 2014 show increase/decrease ratio against theyear ended March 31, 2013
OperatingEarnings
Net Sales
Ordinary Income
Net Income
Incomeper Share
Millions of yen%
Millions of yen%
Millions of yen%
Millions of yen%
Yen
6 months ending Sept. 30, 2013
139,000 18.5
7,300 15.8
5,900
21.8
2,500
(62.2)
14.66
Year ending March 31, 2014
290,000 20.3
15,40035.4
13,300(7.4)
5,200(49.2)
30.49
Note: Revisions to the forecast of consolidated financial results in the current quarter: No

*Notes(1) Change in Significant Subsidiaries during the Current Period(Change in specified subsidiaries caused a change in the scope of consolidation): No
Additional: 0Removal: 0(2) Adoption of Accounting Treatments Simplified or Unique for Preparation: No(3) Change in Accounting Policies and Accounting Estimate and Restatement[1] Changes in accounting policies by a newly issued accounting pronouncement[2] Changes other than [1][3] Change in accounting estimate[4] Restatement

: No
: No
: No
: No

(4) Issued Shares (Common stock)[1] Number of issued shares at end of the period (including treasury stock):
3 months ended June 30, 2013: 171,459,479 sharesYear ended March 31, 2013: 171,459,479 shares[2] Number of treasury stock at end of the period:
3 months ended June 30, 2013: 908,315 sharesYear ended March 31, 2013: 914,107 shares[3] Average number of shares during the period:
3 months ended June 30, 2013: 170,547,387 shares
3 months ended June 30, 2012: 170,545,837 shares*Information regarding the quarterly review procedure
This quarterly summary report is exempt from quarterly review procedure based on the Financial Instruments
and Exchanges Act. It is under the review procedure process at the time of disclosure of this report.
*Disclaimer regarding projection information including appropriate use of forecasted financial result, and otherspecial notes
The projection figures shown above are based on information that was available at the time of preparation and may
contain certain uncertainties. Actual performance and other factors may differ from these projections due tochanges in circumstances and other developments. More information concerning these forecasts can be found in P.4“1. Qualitative Information for the Three-Month Period Ended June 30, 2013, (3) Commentary on Forward-Looking
Statements Including Forecast of Consolidated Financial Results” in the attachment.

Table of Contents

1.

2.

3.

Qualitative Information for the Three-Months Period ended June 30, 20132(1) Commentary on Business Results

2(2) Analysis Concerning Financial Position

4(3) Commentary on Forward-Looking Statements Including Forecast of Consolidated Financial Results

4

Summary (Other) Information

4(1) Changes in Significant Consolidated Subsidiaries

4(2) Accounting Treatments Simplified or Unique for Preparation

4(3) Changes in Accounting Policies and Accounting Estimate and Restatement

4

Consolidated Financial Statements

5(1) Quarterly Consolidated Balance Sheets

5(2) Quarterly Consolidated Statements of Income andQuarterly Consolidated Statements of Comprehensive Income

7

Quarterly Consolidated Statements of Income

7

Quarterly Consolidated Statements of Comprehensive Income

7(3) Notes Regarding Consolidated Financial Statement

8

Notes regarding going concern

8Notes regarding significant changes in the amount of shareholders’ equity

8

Segment Information

8

Significant Subsequent Events

10

-1-

1. Qualitative Information for the Three-Month Period Ended June 30, 2013
(1) Commentary on Business Results
During the current quarter period under review, the global economy generally remained in a mixed situation in which theAmerican economy grew steadily while the credit contraction in Europe, triggered by the debt crisis there, continued.
The Japanese economy, on the other hand, has been back on the recovery path with exports picking up thanks to theongoing yen depreciation and consumer spending remaining solid backed by rising stock prices. The overall management
environment, however, remained in a harsh condition.
Under such circumstances, the Nipro Group has worked to improve operating results through its continued efforts to
expand sales and reduce costs.
As a result, consolidated sales for the three-month period ended June 30, 2013 increased by 19.8% from the same
period of the previous year to 70,093 million yen. As for the profit, consolidated operating income decreased by 27.0%
from the same period of the previous year to 2,534 million yen due to an increase in selling, general and administrative
expenses. Consolidated ordinary income, however, increased by 39.7% from the same period of the previous year to
4,322 million yen thanks to the foreign exchange gains and other factors, and consolidated net income increased by
68.9% from the same period of the previous year to 2,441 million yen.
The overview of the results for the current quarter period under review by business segment is as follows.
Effective from the current quarter period under review, the pharmaceutical product sales unit of Nipro Pharma
Corporation has been integrated into the Company’s Domestic Division. In accordance with this change, the sales unit of
Nipro Pharma Corporation, which had previously been categorized into the Pharmaceutical-Related segment, isreclassified to the Medical-Related segment. The year-on year comparison, however, is not available for the current
quarter period under review, because it is difficult to compare between figures for the segments before and after thereclassification.

(i)

Medical-Related BusinessLooking at the domestic market, a growth opportunity for the Group is increasing amid the ongoing growth strategy of

the current government. The cabinet approved a revision of the Pharmaceutical Affairs Act to simplify and speed up theapproval process of medical equipment by expanding the scope of product certification conducted by privateorganizations.
In addition, the pharmaceutical product sales unit of Nipro Pharma Corporation has been integrated into that of Nipro
Corporation on April 1, 2013. This initiative has synergistically improved the sales capability of the Group as acomprehensive medical company that rests on medical devices (by Medical Sales Division) and pharmaceutical products(by Pharmaceutical Sales Division), and has also enabled the Group to offer a broader range of products and services
more promptly through customer-oriented efforts.
Under such circumstances, sales and profits for the Medical Sales Division from the “HeartMate II (implantableventricular assisting device),” launched in April, and the existing cardiovascular (CVS)-related products such as“extracorporeal ventricular assist devices” increased significantly. Sales were also strong in the fields such as
dialysis-related products, dialysis pharmaceuticals, injection-transfusion-related products, enteral-alimentation-related
products, testing-related products and vascular-related products.
Overseas sales, on the other hand, were robust because export profitability improved significantly thanks to thedepreciation of the yen against the US dollar and Euro during the year. In addition, sales increased significantly from thesame period of the previous year owing to our continued active efforts to enhance and expand our sales network.
By product, we have enhanced the dialysis-related product line, and consequently, sales of the related products such as
artificial kidney (dialyzers), dialysis machines and indwelling needles showed a strong increase. Regarding new overseas
plants, the construction of the plant in India completed at the end of the previous fiscal year, and dialysis-related products
such as dialyzers, needles and syringes showed a steady increase in sales in the Indian market. A production system has
been established at the Indonesian plant as well and sales grew steadily there. At the Hefei plant in China, preparations-2-

for starting operation have progressed smoothly aiming at operation commencement at the earliest possible time.
In the current fiscal year as well, we continue to strive for sales expansion in the fast growing developing countries,
while promoting community-based sales activities.
As a result, net sales of this business were 56,764 million yen.

(ii)

Pharmaceutical-Related Business

The Pharmaceutical-Related Business is roughly classified into two divisions: the Generic Drugs Division, providing
stable supply of high quality and low cost drugs, and the Contracted Manufacturing Division, offering high value-added
products to meet customer needs for various types of drugs.
The market for the Generic Drugs Division is expected to expand further due in part to a government policy to promote
generic drugs; manufactures of original drugs running sideline businesses and foreign generic manufactures haveemerged, making the competitive environment of the domestic market severer.
Under such circumstances, we have worked to expand our market shares of drugs for oral or external use throughcooperation with drug wholesalers, while strengthening the sales promotion to prescribing hospitals and dispensing
pharmacies. In the market for large hospitals, at the same time, we have enhanced information provision activities of
products such as injections. As a result, sales of this division increased steadily.
The Contracted Manufacturing Division, on the other hand, have promoted diligent marketing activities throughproviding various services such as contracted development and support for value adding initiatives, in addition topromoting conventional contracted manufacturing. During the current quarter period under review, sales of this division
increased from the same period of the previous year because we started shipping biopharmaceuticals and major genericdrugs. Furthermore, we have worked to expand contracted manufacturing through joint development with generic drug
sales division and new drug development division of domestic and foreign major pharmaceutical manufactures.
Sales of pharmaceutical containers, medical-preparation- and administration-related devices were strong because wehave made efforts to provide containers and systems suitable for each pharmaceutical product, focusing on various needs
arising from the medical front, such as small volume bags for antimicrobial agents or osteoporosis drugs, materials forpre-filled syringes, etc., on top of rubber stoppers for pharmaceutical and vaccine use and containers for kit products.
These containers and systems were developed by the Group or through joint development with pharmaceuticalmanufactures based on our original processing technologies for plastics, rubbers, and metals. Furthermore, under thegovernment’s policy to curb medical expenses, we have continued to work together with domestic and foreign
pharmaceutical manufactures in enhancing comprehensive lifecycle management of pharmaceutical products, focusing
on the development of combination products, self-injection systems, and dosage form modification in the future.
As a result, net sales of this business were 12,070 million yen.

(iii) Glass-Related Business
Sales of tube glass for ampoules were flat compared to the same period of the previous year thanks to an increase in
one-off orders enjoyed during the current quarter period under review, although downward trend in domestic demand
continued. Sales of tube glass for vials, on the other hand, increased from the same period of the previous year because
sales in the domestic market grew steadily thanks to an increase in orders for vials for vaccines.
Among other glass-related products, sales of thermos bottles decreased from the same period of the previous year due
to a decline in export and weak domestic demand. Regarding glass for lighting purpose, demand for automotive electric
lamp products increased on the back of strong trends in the auto industry, while demand for glass products for lightning
decreased being negatively affected by popularization of LEDs. Thus, although sales of tube glass for electric lamps
increased slightly from the same period of the previous year, overall sales of glass for lighting purpose decreased from thesame period of the previous year due to the weak trends in glass products for lighting.
As a result, net sales of this business were 1,199 million yen.

-3-

(iv) Other BusinessAmong other business, sales from the real-estate rental business were 58 million yen.

(2) Analysis Concerning Financial Position
Analysis Concerning the Conditions of Assets, Liabilities and Net Assets
Total assets increased by 19,812 million yen from the end of the previous year to 599,115 million yen. Current assets
decreased by 8,132 million yen primarily due to a decrease of 21,043 million yen in cash and deposits, and noncurrent
assets increased by 27,945 million yen primarily due to an increase of 17,473 million yen in investment securities.
Total liabilities decreased by 1,713 million yen from the end of the previous year to 448,825 million yen. Current
liabilities increased by 144 million yen primarily due to an increase of 4,079 million yen in notes and accounts
payable-trade, and noncurrent liabilities decreased by 1,858 million yen primarily due to a decrease of 1,658 million yen in
long-term loans payable.
Total net assets increased by 21,526 million yen from the end of the previous year to 150,289 million yen. Shareholders’equity decreased by 241 million yen and accumulated other comprehensive income increased by 21,335 million yen.

(3) Commentary on Forward-Looking Statements Including Forecast of Consolidated Financial Results
Concerning the global economy in the future, the American economy is expected to remain on a recovery path and theemerging economies are expected to recover as well, while the sluggishness of the European economy poses a downsiderisk to the business activities. As to the Japanese economy, an increase in resource prices including those of crude oils isof concern, and companies are taking a cautious stance toward an increase in personnel costs. Thus, the overallmanagement environment is expected to remain in a harsh condition.
Even under such circumstances, the Nipro Group will work to improve profits through its continued efforts to expand
sales and reduce production costs.
At this moment, we have not made any revision to the forecast of consolidated financial results for the year ending
March 31, 2014, which was announced on May 14, 2013.

2. Summary (Other) Information(1) Changes in Significant Consolidated Subsidiaries
N/A(2) Accounting Treatments Simplified or Unique for Preparation
N/A(3) Changes in Accounting Policies and Accounting Estimate and Restatement
N/A

-4-

3. Consolidated Financial Statements(1) [ Quarterly Consolidated Balance Sheets](Millions of yen)
As ofMarch 31, 2013
AssetsCurrent Assets
Cash and deposits
Notes and accounts receivable-trade
Merchandise and finished goods
Work in process
Raw materials and supplies
Deferred tax assets
Other
Allowance for doubtful accounts
Total current assets
Noncurrent assets
Property, plant and equipment
Bulidings and structures
Accumulated depreciation and impairment loss
Buildings and structures, net
Machinery, equipment and vehicles
Accumulated depreciation and impairment loss
Machinery equipment and vehicles, net
Land
Lease assets
Accumulated depreciation
Lease assets, net
Construction in progress
Other
Accumulated depreciation and impairment loss
Other, net
Total property, plant and equipment
Intangible assets
Goodwill
Lease assets
Other
Total intangible assets
Investments and other assets
Investment securities
Deferred tax assets
Other
Allowance for doubtful accounts
Total investments and other assets
Total noncurrent assets
Total assets

-5-

As of
June 30, 2013

106,000
83,66553,89910,48017,275
5,375
11,741(463)
287,974

84,95789,41855,777
10,552
18,398
4,556
16,668(488)
279,841

138,547(69,911)
68,636
170,522(117,991)
52,53022,1733,203(2,029)1,174
23,78633,113(26,712)6,400
174,702

149,880(72,610)
77,270176,884(123,649)
53,234
22,4903,174(2,045)
1,129
21,31534,644(27,885)
6,758
182,198

22,740567
10,95834,26529,681
522
11,474
41,67863,141
8,805
13,767(3,353)82,360291,328
579,30280,614
3,549
14,648(3,416)65,396319,273
599,115

(Millions of yen)
As ofMarch 31, 2013
Liabilities
Current liabilities
Notes and accounts payable-trade
Short-term loans payable
Commercial papers
Current portion of bonds
Lease obligations
Accounts payable-otherAccrued directors' bounuses
Income taxes payable
Provision for bounuses
Provision for directors' bounuses
Provision for loss on business liquidation
Notes payable-facilities
Other
Total current liabilities
Noncurrent liabilities
Bonds payable
Convertible bond-type bonds
with subscription rights to shares
Long-term loans payable
Lease obligations
Deferred tax liabilities
Provision for retirement benefits
Provision for directors' retirement benefits
Provision for loss on litigation
Other
Total noncurrent liabilities
Total liabilities
Net assets
Shareholders' equity
Capital stock
Capital surplus
Retained earnings
Treasury stock
Total shareholders' equity
Accumulated other comprehensive income
Valuation difference on available-for-sale securities
Foreign currency translation adjustment
Total accumulated other comprehensive income
Minority interests
Total net assets

-6-

As of
June 30, 201340,878127,238
10,000
1,277
1,011
8,286
316
4,266
2,810
70
1,954
3,734
11,912
213,758

44,958128,269
10,000
1,252
982
6,839

47,14746,855

14,90014,895

164,906
2,040
2,212
2,854
742
218
1,757
236,780
450,539

163,248
1,946
2,282
2,969
757
218
1,749
234,922448,825

84,397636
54,788(865)
138,957

84,397635
54,542(859)
138,715(12,547)(6,436)(18,983)
8,789
128,763(1,182)
3,534
2,352
9,221
150,289

2,864
1,842
85
1,954
1,147
13,705
213,902(2) [Quarterly Consolidated Statements of Income and Quarterly Consolidated Statement of Comprehensive Income]Quarterly Consolidated Statements of Income(Amount: million yen)
FY2012 first three months(From April 1, 2012
to June 30, 2012)
Net sales
Cost of sales
Gross profit
Selling, general and administrative expenses
Operating income
Non-operating income
Interest income
Dividends income
Foreign exchange gain
Other
Total non-operating income
Non-operating expenses
Interest expenses
Foreign exchange losses
Equity in losses of affiliates
Other
Total non-operating expenses
Ordinary income
Extraordinary income
Gain on sales of noncurrent assets
State subsidy
Gain on negative goodwill
Compensation income
Other
Total extraordinary income
Extraordinary loss
Loss on retirement of noncurrent assets
Loss on reduction of noncurrent assets
Company funeral expenses
Structural integration expenses
Other
Total extraordinary losses
Income before income taxes and minority interests
Income taxes-current
Income taxes-deferred
Total income taxes
Income before minority interests
Minority interests in income
Net income

FY2013 first three months(From April 1, 2013
to June 30, 2013)

58,532
42,197
16,335
12,861
3,473

70,09350,06420,02917,494
2,534

232
860
－
214
1,306

221
940
1,461
322
2,946

845
757
24
60
1,687
3,092

971
－
－
187
1,158
4,322

24
40
39
－
8
113

199
1
4
570
70
846

21
29
40
－
15
107
3,099
1,040
549
1,589
1,509
64
1,445

17
－
－
30
14
62
5,106
2,361
261
2,622
2,483
42
2,441

[Qarterly Consolidated Statements of Comprehensive Income](Amount: million yen)
FY2012 first three months(From April 1, 2012
to June 30, 2012)
Income before minority interests
Other comprehensive income
Valuation difference on available-for-sale securities
Foreign currency translation adjustment
Total other comprehensive income
Comprehensive income
Comprehensive income attributable to owners of the parent
Comprehensive income attributable to minority interests-7-

FY2013 first three months(From April 1, 2013
to June 30, 2013)

1,509

2,483

(10,074)
5,783(4,291)(2,781)(2,887)106

11,364
10,506
21,871
24,354
23,777577

(3) Notes Regarding Consolidated Financial Statement(Notes regarding going concern)
N/A(Notes regarding significant changes in the amount of shareholders’ equity)
N/A(Segment Information)Ⅰ

FY2012 (From April 1, 2012 to June 30, 2012)

1.

Sales and Profit by Reportable Operating Segment(Millions of yen)Segment
MedicalRelated

PharmaceuticalRelated

GlassRelated

Total

Other
(Note.1)

Total

Adjustment(Note.2)

Consolidated
Statements ofIncome(Note.3)

Net sales(1)Sales to third parties

40,634

16,6681,171

58.47458

58,532－58,532(2)Inter-segment sales
and transfers

290

1,665

105

2,061

11

2,073

(2,073)－

Total

40,924

18,333

1,277

60,53569

60,605(2,073)58,532

Segment profit

3,664

1,657

197

5,519

54

5,574

(2,101)

3,473(Notes)
1.
2.

3.
2.

“Other” is the business segment which is not included in the segment and consist of real estate income and sales
by headquarter.
Adjustment for the segment profit of (2,101) million yen includes elimination of inter-segment transaction of (251)
million yen and corporate cost of (1,849) million yen. Corporate cost consisted primarily of general andadministrative expenses and research and development cost which do not belong to the reporting segment.
Segment profit is adjusted to the operating income on the consolidated statements of income.

Information about Impairment Loss on Fixed Assets and Goodwill by Reportable Operating Segment
N/A

-8-

Ⅱ
1.

FY2013 (From April 1, 2013 to June 30, 2013)
Sales and Profit by Reportable Operating Segment(Millions of yen)Segment
MedicalRelated

PharmaceuticalRelated

GlassRelated

Total

Other
(Note.1)

Total

Adjustment(Note.2)

Consolidated
Statements ofIncome(Note.3)

Net sales(1)Sales to third parties

56,764

12,0701,199

70,03458.

70,093－70,093(2)Inter-segment sales
and transfers

308

1,787

136

2,233

10

2,243

(2,243)－

Total

57,073

13,858

1,336

72,26868

72,336(2,243)70,093

Segment profit

3,634

2,128

143

5,906

54

5,961

(3,426)2,534(Notes)1.
2.

3.

“Other” is the business segment which is not included in the segment and consist of real estate income and sales
by headquarter.
Adjustment for the segment profit of (3,426) million yen includes elimination of inter-segment transaction of(1,113) million yen and corporate cost of (2,313) million yen. Corporate cost consisted primarily of general andadministrative expenses and research and development cost which do not belong to the reporting segment.
Segment profit is adjusted to the operating income on the consolidated statements of income.

2. Changes in Reportable Segments(1) Effective from the third quarter period ended December 31, 2012, the name of the following reportable businesssegment has been changed: from “Materials” to “Glass-Related.”
This arrangement only involves a change in the name of the business segment, and classification has not beenchanged from the first quarter period ended June 30, 2012. Reflecting this change, the segment information for the
first quarter period ended June 30, 2012 is presented using the revised name.
(2) Effective from the third quarter period ended December 31, 2012, we have partially changed our organization sothat we can strengthen the Pharmaceutical-Related Business further and facilitate close coordination between the
Medical-Related Business and the Glass-Related Business. In accordance with this change, a part of businessdivisions, which had previously been categorized into the Glass-Related segment, has been reclassified to thePharmaceutical-Related segment.
The segment information for the first quarter period ended June 30, 2012 is prepared based on the reportablesegments after the reclassification.
(3) Effective from the quarter period under review, the pharmaceutical product sales unit of Nipro Pharma Corporation
has been integrated into the Company’s Domestic Division so that we can enhance our management capability
through close coordination between the three divisions: the Medical Devices Division, the Pharmaceutical
Products Division, and the Glass and Materials Division. In accordance with this change, the sales unit, which had
previously been categorized into the Pharmaceutical-Related segment, is reclassified to the Medical-Related
segment.
The segment information for the first quarter period ended June 30, 2012 after reclassification, except for sales
to external customers, is not available to the public, because accurately and retrospectively extracting data forcost of sales and selling, general and administrative expenses is practically difficult. In addition, the segment
information for the current quarter period under review based on the segments before the reclassification is notavailable to the public either, because it is practically difficult to obtain necessary information to prepare it.
Sales to the external customers for the first quarter period ended June 30, 2012, if prepared based on thesegments before the reclassification, would have been 45,704 million yen for the Medical-Related segment and11,597 million yen for the Pharmaceutical-Related segment.
(4) Effective from the current quarter period under review, Chengdu Pingyuan Nipro Pharmaceutical Packaging Co.,
Ltd., Jilin Nipro Jiaheng Pharmaceutical Packing Co., Ltd. and Anyang Nipro Changda Pharmaceutical Packaging
Co., Ltd., which had previously been categorized into the Glass-Related segment, are reclassified to theMedical-Related segment, as a result of review and re-examination as part of our international management
strategy.
The segment information for the first quarter period ended June 30, 2012 is prepared based on the reportablesegment after the reclassification.

-9-

3. Information on Impairment Loss on Fixed Assets and on Goodwill by Reportable Segment(Material Change in the Amount of Goodwill)In the Medical-Related segment, Nichihos Co., Ltd. and its 10 subsidiary companies have been included in the scope of
consolidation as a result of acquition of their shares. As a result, unamortized balance of goodwill increased 6,851 million
yen from the end of the previous period.

(Significant Subsequent Events)
Acquisition and Tender Offer of Treasury Stocks
Based on the Board of Directors meeting dated May 14, 2013, the Company acquired treasury stocks, by means oftender offer (“Tender Offer”) to be specific, pursuant to the provisions of Article 156, Paragraph 1 of the Companies Act(Law No. 86 of 2005, as amended, “the Act”), applied by replacing certain terms provided pursuant to Article 165,
Paragraph 3 of the Act, and the provisions of the Company’s Articles of Incorporation.
1. Outline of the Tender Offer, etc.
Class of Shares:
Total Number of Shares:
Purchase Price:
Funds Required for Purchase:
Period of Tender Offer:

Common Stock
37,721,000 shares
862 yen per common stock
32,539 million yen
From May 15, 2013 (Wednesday)
through June 11, 2013 (Tuesday)(20 business days in Japan)

2. Results of the Tender Offer, etc.
Number of Tendered Shares:
19,834,000 shares
Number of Shares Purchased:
19,834,000 shares(Note) Percentage to the total shares issued: 11.57% (rounded to the two decimal points)
3. Results of the Acquisition of Treasury Stocks
Class of Shares Purchased:
Common Stock
Total Number of Shares Purchased: 19,834,000 shares
Total Acquisition Value:
17,096 million yen(Note) Commissions to be paid to the tender offer agent and other expenses are not included in the above value.
Date of Acquisition:
July 4, 2013- 10 -